Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicobion
- Development stage
- Preclinical
- Lead developer
- Centre Hospitalier Universitaire d'Angers
- Administration
- Oral, Intravenous, Intramuscular, Subcutaneous
01
Overview
Nicobion appears to be a named investigational intervention associated with Centre Hospitalier Universitaire D'Angers for **Leber's hereditary optic neuropathy**. Based on the available contextual evidence, it is most plausibly a pharmaceutical neuro-ophthalmic candidate intended for LHON, a mitochondrial genetic optic neuropathy, but the exact active substance, formulation, modality, and molecular mechanism could not be established with confidence from the information provided. Because the chemical identity is not reliably resolved, its mechanism of action and development details should be treated as unconfirmed.
- Other names
- Nicobion
Beyond the preview
Go deeper on Nicobion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicobion.